115 results on '"Salles, Jean Pierre"'
Search Results
2. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial
3. Adult Height Improved Over Decades in Patients with X-Linked Hypophosphatemia: a cohort study
4. THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials
5. OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study
6. THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib
7. Growth hormone dose modulation and final height in short children born small for gestational age: French real-life data
8. Growth hormone treatment improves final height in children with X-linked hypophosphatemia
9. PSAT105 Evaluation of Body Mass Index and Metabolic Parameters in Children with Achondroplasia Participating in the PROPEL Study
10. Obesity, Overweight, and Pituitary Stalk Interruption Syndrome in Children and Young Adults
11. Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience
12. X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study
13. Diagnostic yield of bone fragility gene panel sequencing in children and young adults referred for idiopathic primary osteoporosis at a single regional reference centre
14. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
15. WNT11, a new gene associated with early onset osteoporosis, is required for osteoblastogenesis
16. Prenatal features and neonatal management of severe hyperparathyroidism caused by the heterozygous inactivating calcium-sensing receptor variant, Arg185Gln: A case report and review of the literature
17. Low bone mass in Noonan syndrome children correlates with decreased muscle mass and low IGF-1 levels
18. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience
19. Clinical Forms and Animal Models of Hypophosphatasia
20. Biochemical assessment of phosphate homeostasis
21. SNORD116 and growth hormone therapy impact IGFBP7 in Prader–Willi syndrome
22. Patients with PWS and related syndromes display differentially methylated regions involved in neurodevelopmental and nutritional trajectory
23. Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?
24. Is ghrelin a biomarker of early-onset scoliosis in children with Prader–Willi syndrome?
25. Prader-Willi Syndrome as a Model of Human Hyperphagia
26. SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations
27. A standard set of outcome measures for the comprehensive assessment of osteogenesis imperfecta
28. Hypophosphatasia: A Case of Two Patients With Spinal Cord Compression From Increase in Ligamentous Ossifications During Treatment
29. Utility of genetic testing for prenatal presentations of hypophosphatasia
30. Presenting features and molecular genetics of primary hyperparathyroidism in the paediatric population
31. A Standard Set of Outcome Measures for the Comprehensive Assessment of Osteogenesis Imperfecta.
32. Lysophosphatidic Acid (LPA) Signaling and Bone
33. Ghrelin uses the GHS-R1a/Gi/cAMP pathway and induces differentiation only in mature osteoblasts. This ghrelin pathway is impaired in AIS patients
34. Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch
35. Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study
36. What can we learn from PWS and SNORD116 genes about the pathophysiology of addictive disorders?
37. The type 1 lysophosphatidic acid receptor is involved in osteoblastogenesis up to osteocytogenesis
38. Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?
39. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification
40. A Standard Set of Outcome Measures for the Comprehensive Assessment of Osteogenesis Imperfecta.
41. Demographic Characteristics, Risk Factors, and Presenting Features of Children with Symptomatic Nutritional Rickets: A French Series
42. Gene expression signatures predict response to therapy with growth hormone
43. Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency
44. Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study
45. Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity
46. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia
47. Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth
48. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)
49. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial
50. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader–Willi Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.